Vote Scores
Filings read through

Viking Therapeutics, Inc.: how funds voted at the meeting of 19 May 2026

Ticker
VKTX
Meeting
Season
year to 30 June 2026
Filers reporting
529
Ballot items
4

529 filers on Form N-PX reported votes at the Viking Therapeutics, Inc. meeting of 19 May 2026. The records fall into 4 ballot items. The page lists them in ballot order: items of the company first, then proposals from security holders. Each bar shows how the reporting filers split. It is not the result of the meeting.

If the reporting person has not received confirmation of the actual number of votes cast prior to filing a report on Form N-PX, the numbers reported may reflect the number of shares instructed to be cast. A reporting person is not required to amend a previously filed Form N-PX report if the reporting person subsequently receives confirmation of the actual number of votes cast.

The words of the SEC. Source: Form N-PX and its instructions, Special Instructions D.5 and D.8, copied on .

The words of this site: the filer writes each filing. The SEC does not say that it checked the votes. A lender does not vote shares that are on loan. A later filing (Form N-PX/A) can replace an earlier filing, and the site uses the latest.

The figures on this page count the filers that report on Form N-PX and the shares they reported. They do not count all votes cast at the meeting.

The page gives records. It gives no investment advice and no advice on how to vote.

Season on this page: year to 30 June 2026. Filings read through . How the figures are made

The ballot

ForAgainstAbstain, withhold or otherAmber tick: the part cast against management

  1. Item 1: Director elections

    2 nominees. 40.5% of the reported votes are for. 104 filers withheld from or voted against at least one nominee.

    542 vote records from 134 filers. 61 of the 131 filers that marked the item voted against management. 3 filers gave no management mark.

    • Positions of 32 fund families
    • For 6
    • Abstain or withhold 19
    • Split or no vote 7
    • Against management 18
  2. Item 2: Advisory vote on executive pay (say-on-pay)

    741 vote records from 525 filers. 197 of the 488 filers that marked the item voted against management. 37 filers gave no management mark.

    • Positions of 41 fund families
    • For 17
    • Against 23
    • Split or no vote 1
    • Against management 22
  3. Item 3: Audit-related items (auditor ratification)

    271 vote records from 134 filers. 2 of the 131 filers that marked the item voted against management. 3 filers gave no management mark.

    • Positions of 32 fund families
    • For 32
  4. Item 4: COMPENSATION: management items

    The company's items in this category are shown together, because filers word and number them differently.

    12 vote records from 8 filers. 1 of the 8 filers that marked the item voted against management.

    • Positions of 2 fund families
    • Against 2
    • Against management 1

Positions of the fund families

A position is not the vote of each fund. The position of a family is the way most of the shares reported by its filers were voted. Funds of one family can vote in different ways.

KeyForAgainstAbstain or withholdSplit or no voteAgainst management

Fund families at Viking Therapeutics, Inc., meeting of 19 May 2026Families in name order. "Abstain" includes withhold. "Split" includes no vote. "No report" means that no filer of the family listed the item.
Fund family2. Say-on-pay3. Auditor
AllianceBernsteinAgainst, against managementNo report
AllspringSplitNo report
American CenturyAgainst, against managementFor
BairdForNo report
BlackRock and iSharesAgainst, against managementFor
BNY MellonAgainst, against managementFor
Charles SchwabForFor
Columbia ThreadneedleAgainst, against managementFor
DimensionalAgainst, against managementFor
DWSAgainst, against managementNo report
EquitableAgainst, against managementFor
FidelityForFor
First TrustAgainst, against managementFor
Franklin TempletonAgainst, against managementNo report
Goldman SachsForFor
Guggenheim and RydexAgainst, against managementFor
Harbor FundsForFor
InvescoAgainst, against managementFor
J.P. MorganForFor
Jackson National fundsAgainst, against managementFor
John Hancock and ManulifeAgainst, against managementFor
Lincoln FinancialAgainstFor
Macquarie and Delaware FundsAgainst, against managementFor
MassMutualForNo report
Morgan Stanley, Eaton Vance and CalvertAgainst, against managementNo report
Natixis and Loomis SaylesForNo report
Neuberger BermanForNo report
Northern Trust and FlexSharesAgainst, against managementFor
Nuveen and TIAAForFor
Pacific Life fundsAgainst, against managementFor
PGIM and PrudentialAgainst, against managementFor
PrincipalForFor
ProShares and ProFundsAgainst, against managementFor
Russell InvestmentsForFor
SEIForFor
State Street and SPDRForFor
T. Rowe PriceAgainst, against managementFor
VanguardForFor
Victory CapitalAgainst, against managementFor
VoyaForFor
WisdomTreeForFor

Questions

How many filers reported votes at the Viking Therapeutics, Inc. meeting?
529 Form N-PX filers reported votes at the meeting of 19 May 2026. On say-on-pay, 197 of 488 filers that marked the item voted against management (40.4%).
Is this the result of the meeting?
No. The page counts the filers that report on Form N-PX, and the shares they reported. Viking Therapeutics, Inc. reports the result of a vote on Form 8-K.
Why does the page show counts only for director elections?
A director record names the nominee. This site has no page and no row about a person. For director elections it keeps the number of nominees and the split of votes.

Provenance: SEC EDGAR, Form N-PX and N-PX/A filings that list Viking Therapeutics, Inc. with a meeting date within three days of 19 May 2026. A proposal title is the most common wording among filers. Where a wording can name a person, the SEC category is shown. The filers wrote the filings. Filings read through .